PureTech Health (LSE:PRTC) Short-Term Debt : £3.25 Mil (As of Dec. 2024)

View and export this data going back to 2015. Start your Free Trial

What is PureTech Health Short-Term Debt?

PureTech Health's Short-Term Debt for the quarter that ended in Dec. 2024 was £3.25 Mil.

PureTech Health's quarterly Short-Term Debt increased from Dec. 2023 (£2.92 Mil) to Jun. 2024 (£3.17 Mil) and increased from Jun. 2024 (£3.17 Mil) to Dec. 2024 (£3.25 Mil).

PureTech Health's annual Short-Term Debt declined from Dec. 2022 (£6.16 Mil) to Dec. 2023 (£2.92 Mil) but then increased from Dec. 2023 (£2.92 Mil) to Dec. 2024 (£3.25 Mil).

PureTech Health Short-Term Debt Historical Data

The historical data trend for PureTech Health's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PureTech Health Short-Term Debt Chart

PureTech Health Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Short-Term Debt

Get a 7-Day Free Trial

19.68

4.13

6.16

2.92

3.25

PureTech Health Semi-Annual Data
	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Short-Term Debt	Get a 7-Day Free Trial															6.16	1.87	2.92	3.17	3.25

PureTech Health Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

PureTech Health Short-Term Debt Related Terms

Thank you for viewing the detailed overview of PureTech Health's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

PureTech Health Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PureTech Health PLC (LSE:PRTC) » Definitions » Short-Term Debt

Comparable Companies

Traded in Other Exchanges

PRTC:USA PTCHF:USA PRTCl:UK 0VQ:Germany

Address

6 Tide Street, Suite 400, Boston, MA, USA, 02210

Website

https://www.puretechhealth.com

PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.